SI Results

Supplementary Figure 1. Imatinib-resistant K562 R and AR230 R cells demonstrate cross-resistance to nilotinib and dasatinib. (a-c) TKI-resistant K562
R and AR230 R cells were treated with graded concentrations of either imatinib (a), nilotinib (b), or dasatinib (c) for 6 hours followed by MTS assay. IC 50 values were calculated and compared to that of TKI-sensitive parental controls. Curves represent normalized absorbance at 490 nm from three independent experiments. Bar graphs represent the relative IC 50 values for TKI-resistant (R) and TKI-sensitive (S) cell lines across replicates (n=3). Error bars represent SEM. *p<0.05.
Supplementary Figure 2. STAT3 activation in TKI-resistant K562
R and AR230 R cells. TKI-sensitive (S) and TKI-resistant (R) K562 and AR230 cells were treated with graded concentrations of imatinib, nilotinib, or dasatinib (see Supplementary Figure S1 ) for 6 hr, followed by immunoblot with the specified antibodies. These data demonstrate partial but not full dependence of pSTAT3 Y705 on SRC family kinases, which is consistent with previous reports 1- 4 .
Supplementary Figure 3. pSTAT3 Y705 is activated in CML cell lines and CD34 + patient samples with extrinsic TKI resistance through growth in HS-5 conditioned medium (CM). (a and b)
TKI-sensitive and TKI-resistant CML cell lines were cultured in RM or HS-5 CM for 24 hours in the presence or absence of the indicated concentrations of imatinib followed by immunoblot analyses with the specified antibodies (n=3). Regardless of TKI sensitivity, imatinib suppressed BCR-ABL1 kinase activity, verifying BCR-ABL1 kinaseindependent resistance mechanisms. This is true even in K562 R cells which demonstrate enhanced levels of BCR-ABL1 protein.
Supplementary Figure 4. STAT3 inhibition reduces survival and increases apoptosis of TKI-resistant but not TKI-sensitive K562 cells. (a and b)
Parental K562 cells were lentivirally infected with shSTAT3 or shSCR, followed by culture in RM or HS-5 CM in the presence or absence of imatinib (2.5 µM). After 36 hours in culture, cells were either plated in semisolid medium with colonies scored after 7 days (a, n=3) or analyzed for apoptosis by staining with an Annexin V-specific antibody (b, n=4). As expected, shSTAT3 inhibited cells only when cells were cultured in HS-5 CM and not when cultured in RM. Error bars represent SEM. *p<0.05; ***p<0.001. Figure 5 . A luciferase reporter screen identifies first-generation STAT3 inhibitors with greater potency and selectivity than the parent compound, SF-1-066. (a) A drug development pipeline was used to identify STAT3 inhibitors with greater potency and selectivity than SF-1-066. (b) AR230 R -SIE (reporter) or AR230 R -NEG (mutated reporter) cells were produced by lentiviral transduction of sequences harboring either sequential STAT3-inducible elements (SIE) or a mutated negative control sequence (NEG). These were cloned into the pGF1 luciferase reporter construct and introduced by lentiviral delivery. (c) The functional groups of the salicylic-acid scaffold were altered to possess additional functionality on the sulfonamide nitrogen position, which is designated as R 1 . (d) Compounds from panel C were screened in the luciferase reporter assay at 10 µM and ranked based on potency and selectivity. Figure 6 . Inhibition of the STAT3 SH2 domain with small-molecule salicylic acidbased STAT3 inhibitors. (a and b) The inherent flexibility of the STAT3 SH2 domain suggested use of the induced-fit docking simulation. Since low energy conformations were generated using the initial GlideXP module (version 5.7), the binding pose was enhanced to allow receptor flexibility using Glide induced-fit docking. Inherent flexibility of the STAT3 SH2 domain was observed as thermal fluctuations in X-ray crystallography experiments. Using this approach, a ≥2 kcal/mol gain in free binding energy for BP-5-087 compared to SF-1-066 was demonstrated. (c) Growth factor receptor engagement leads to recruitment of unphosphorylated STAT monomers and dimers for phosphorylation at Y705 (1), followed by SH2-dependent dimerization and nuclear translocation (2) . BP-5-087 is predicted to reduce dimerization and phosphorylation at Y705 (3), thereby blocking nuclear transactivation (4) in CML cells with BCR-ABL1 kinase-independent TKI resistance. Y705 is consistently activated in all conditions of TKI resistance. Interestingly, activation of JAK2 and AKT, as well as upregulation of β-catenin, was observed in intrinsic but not extrinsic resistance. Tables   Supplementary Table 1 
Supplementary
SI
Additional assay(s)
Results were compared to EC50 values as assessed in fluorescence polarization assays.
Confirmation of hit purity and structure
Final molecules were characterized by 1 H and 13 C NMR and high resolution mass spectrometry. Inhibitor purity was evaluated by analytical reversed-phase HPLC.
STAT3 indicates signal transducer and activator of transcription 3; TKI, tyrosine kinase inhibitor; JAK, Janus kinase; SIE, STAT3-inducible element; NEG, negative control sequence. were Ficoll-separated and used for automated isolation of the CD34 + fraction using an autoMACS Pro (Miltenyi Biotech). Purity was determined to be >90% by fluorescence activated cell sorting (FACS). Prior to use in assays, CD34 + progenitors from CML patients were kept overnight in RPMI containing 20% BIT9500 (Stem Cell Technologies), 100 U/mL penicillin-streptomycin, and 2 mM L-glutamine (GIBCO), without addition of cytokines. Where indicated, 96-hour CML CD34 + cell assays were performed in the absence of cytokines. All cells were confirmed to harbor exclusively native BCR-ABL1 using conventional Sanger sequencing in both directions with BigDye terminator chemistry on an ABI3730 instrument 5 . All patients gave their informed consent in accordance with the Declaration of Helsinki, and all studies with human specimens were approved by The University of Utah Institutional Review Board (IRB). 
SI Materials and Methods
Cell cultures and primary cells
HS-5 CM protection assays
Plasmids
For vectors containing STAT3-specific shRNAs, pSIH1-puro-shSCR (plasmid 26597) and pSIH1-puro- 
Fluorescence polarization (FP) assay
To assess STAT3 SH2 domain binding, a high-throughput FP assay was used as previously described 6 .
Briefly, STAT3 protein (150 nM), fluorescently labeled peptide probe (5-aminofluorocein-GpYLQTV, 10 nM), and varying concentrations of potential inhibitors were combined in black, flat bottom 384-well plates.
After 30 minutes, polarized fluorescence was measured using a Tecan M1000 fluorimeter, and plotted as a function of concentration. EC50 values were determined by fitting to a standard dose response curve.
Luciferase inhibitor screen
To detect endogenous pSTAT3 Y705 activity, we transduced AR230 R cells with the pGreenFire Lenti-Reporter system (pGF1; System Biosciences) harboring either two sequential STAT3 sis-inducible elements (SIE) or negative control (NEG) sequences. The oligonucleotide sequence used to clone the SIE was:
5'-GTCGACATTTCCCGTAAATCGTCGAGTCGACATTTCCCGTAAATCGTCG-3'. The sequence used for the NEG was: Figure 4a) . Reporter plasmids were made by cloning PCR-amplified sequences (including the Xba1 and EcoR1 restriction sites), double digestion with Xba1 and Spe1, and ligation into the mCMV-pGF1 reporter construct (pGF1-SIE and pGF1-NEG). AR230 R (3x10 5 cells) expressing either pGF1-SIE (AR230 R -SIE) or pGF1-NEG (AR230 R -NEG) were treated with 20% HS-5 CM and exposed to imatinib (1.0 µM) and/or STAT3 inhibitors (5-10 µM) for 6 hours, followed by detection of luciferase reporter activity on a GloMaxMulti Detection System: Luminometer (Promega, E7041) using the OneGlo luciferase kit (Promega). The relative ratio of AR230R-SIE to AR230R-NEG vs. untreated control was used to rank compounds and select BP-5-087. Potency was ranked according to percent luciferase inhibition in AR230R-SIE transfected cells.
Specificity was ranked according to the difference in inhibition between AR230R-SIE and AR230R-NEG cells. were analyzed on a QStar Elite mass spectrometer (AB Sciex). Peptic peptides were identified on the MS spectra by precise mass matching using the FindPept tool (ExPASy), and confirmed by CID MS/MS whenever possible. Isotopic distribution envelope was used to determine percent deuterium uptake for each peptide by computing the best fit of observed data to modeled isotopic distributions. Resulting deuterium uptake time-series were fitted to a single exponential rise to the max function, and the amplitude parameter was used to calculate fold deuterium uptake difference as a ratio of percent deuterium uptake in MBP-STAT3:BP-5-087 to MBP-STAT3:DMSO samples.
Docking simulations
Chemical methods
Anhydrous solvents: methanol (MeOH), chloroform, dimethylsulfoxide (DMSO), CH 2 Cl 2 , tetrahydrofuran (THF), and dimethylformamide (DMF) were purchased from Sigma Aldrich and used directly from SureSeal bottles. Unless otherwise indicated, reactions were performed under an atmosphere of dry nitrogen and were monitored for completeness by thin-layer silica gel chromatography (visualized by UV light, or developed by treatment with KMnO 4 stain). All compounds were purified by silica gel column chromatography which was performed using a Biotage Isolera One automated flash chromatography system.
Intermediate compounds were characterized using 1 H and 13 C NMR. Final molecules were characterized by 1 H and 13 C NMR and high resolution mass spectrometry. Before biological testing, inhibitor purity was evaluated by analytical reversed-phase HPLC (rpHPLC). Analysis by rpHPLC was performed using a Microsorb-MV 300 Å C18 250 mm x 4.6 mm analytical column run at 1 mL/min and gradient mixtures of 
